Ratings Plastivaloire

Equities

PVL

FR0013252186

Market Closed - Euronext Paris 11:35:09 2024-07-16 am EDT 5-day change 1st Jan Change
1.89 EUR -0.26% Intraday chart for Plastivaloire -1.56% -48.78%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The stock, which is currently worth 2024 to 0.31 times its sales, is clearly overvalued in comparison with peers.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company has a low valuation given the cash flows generated by its activity.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Commodity Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
-48.78% 45.6M -
-0.41% 37.46B
B-
-31.56% 19.68B
B-
+4.10% 11.27B
A-
-27.78% 11.19B
B-
+27.67% 8.89B
C+
-22.31% 8.66B
B+
-13.30% 5.28B
C+
-46.97% 3.98B
C
-29.70% 3.34B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PVL Stock
  4. Ratings Plastivaloire